No Data
No Data
Xiangyu Medical (688626.SH): A total cost of 75.385,000 yuan to buy back 1.1% of the shares
Gelonghui, May 7, 丨 Xiangyu Medical (688626.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,761,012 shares of the company through centralized bidding transactions, accounting for 1.1006% of the company's total share capital of 160,000,000 shares. The highest price of the repurchase transaction was 52.19 yuan/share, the lowest price was 32.70 yuan/share, and the total amount of capital paid was RMB 75,385,243.15 (not including transaction fees and transfer fees).
Xiangyu Healthcare (688626): Industry-university-research innovation advantages highlight driving both revenue and profit growth
Event: The company released the 2023 annual report and the first quarter report of 2024. The company achieved operating income of 745 million yuan (+52.46%) in 2023; net profit to mother of 227 million yuan (+81.03%)
Express News | Xiangyu Healthcare: The “trade-in” program has been launched and will continue to thoroughly study national policies and actively seize this market opportunity
Guoxin Securities released a research report on April 25 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in performance in 2023, strong recovery in demand for rehabilitation d
Guoxin Securities released a research report on April 25 stating that it gave Xiangyu Healthcare (688626.SH) a purchase rating. The main reasons for the rating include: 1) rapid growth in performance in 2023, strong recovery in demand for rehabilitation devices after the epidemic; 2) increased profitability and lower cost rates; 3) the first equity incentives after launch, demonstrating confidence in development. (Mainichi Keizai Shimbun)
Xiangyu Medical (688626): Net profit due to mother increased by 81% in 2023 and continued to increase R&D investment
Performance grew rapidly in 2023, and demand for rehabilitation devices recovered strongly after the pandemic. In 2023, the company achieved revenue of 745 million yuan (+52.46%), net profit attributable to mother of 227 million yuan (+81.03%), after deduction
Xiangyu MedicalLtd's (SHSE:688626) Performance Raises Some Questions
Investors were disappointed with Xiangyu Medical Co.,Ltd's (SHSE:688626) recent earnings release. We did some digging and found some underlying numbers that are worrying. SHSE:688626 Earnings and
No Data